Onkológia 6/2013

Essential thrombocythemia

Essential thrombocythemia (ET) is representative of the myeloproliferative neoplasms without the presence of the Philadelphia chromosome (Ph chromosome) disease, also referred as Ph negative myeloproliferative neoplasms (Ph-negative MPN). ET is its subunit, which in comparison with other classical clinical subgroups of Ph-negative MPN (primary myelofibrosis, polycythaemia vera) has a relatively benign clinical course. However, differential diagnosis, clinical stratification and treatment selection may lead to bad decisions, which may change original benign course of the disease and increase the incidence of serious complications. In this article, in addition to the characteristics of the disease, draws attentions to the need for personalization treatment ET, which is assumption for the safe management.

Keywords: essential thrombocythemia, personalized medicine, risk stratification, anagrelid, interferon alpha, hydroxyurea, safe management.